Get the Stockscreener App
6.00
0.17%
-0.010
After Hours:
6.09
0.09
+1.50%
Verve Therapeutics Inc stock is currently priced at $6.00, with a 24-hour trading volume of 1.76M.
It has seen a -0.17% decreased in the last 24 hours and a -53.09% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.09 pivot point. If it approaches the $5.87 support level, significant changes may occur.
Previous Close:
$6.01
Open:
$6.04
24h Volume:
1.76M
Market Cap:
$503.54M
Revenue:
$11.76M
Net Income/Loss:
$-200.07M
P/E Ratio:
-1.8927
EPS:
-3.17
Net Cash Flow:
$-158.83M
1W Performance:
-8.81%
1M Performance:
-53.09%
6M Performance:
-48.94%
1Y Performance:
-62.59%
1D Range:
$5.84
$6.56
52W Range:
$5.84
$21.42
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
617-603-0070
Address
500 Technology Square, Suite 901, Cambridge
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Zacks Investment Research
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Benzinga
After a Serious Setback, Is Verve Therapeutics a Buy?
The Motley Fool
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
Benzinga
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Zacks Investment Research
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
Benzinga
Verve Therapeutics Inc Stock (VERV) Financials Data
Verve Therapeutics Inc (VERV) Revenue 2024
VERV reported a revenue (TTM) of $11.76 million for the quarter ending December 31, 2023.
Verve Therapeutics Inc (VERV) Net Income 2024
VERV net income (TTM) was -$200.07 million for the quarter ending December 31, 2023, a -27.12% decrease year-over-year.
Verve Therapeutics Inc (VERV) Cash Flow 2024
VERV recorded a free cash flow (TTM) of -$158.83 million for the quarter ending December 31, 2023, a -17.16% decrease year-over-year.
Verve Therapeutics Inc (VERV) Earnings per Share 2024
VERV earnings per share (TTM) was -$3.12 for the quarter ending December 31, 2023, a -6.85% decline year-over-year.
About Verve Therapeutics Inc
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.
3.18%
Cap:
|
Volume (24h):